# Hideki Enokida

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3856524/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 107 papers | 7,263 citations | 34105 52 h-index | 56724 83 g-index |
| 110 all docs | 110 docs citations | 110 times ranked | 9542 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Efficacy of combined androgen blockade therapy in patients with metastatic hormoneâ€sensitive prostate cancer stratified by tumor burden. International Journal of Urology, 2022, , . | 1.0 | 4 |
| 2 | microRNAâ€99aâ€5p induces cellular senescence in gemcitabineâ€resistant bladder cancer by targeting SMARCD1. Molecular Oncology, 2022, 16, 1329-1346. | 4.6 | 13 |
| 3 | Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. Biochemical and Biophysical Research Communications, 2022, 611, 99-106. | 2.1 | 4 |
| 4 | Radiotherapy plus androgen deprivation therapy for prostateâ€specific antigen persistence in lymph nodeâ€“positive prostate cancer. Cancer Science, 2022, 113, 2386-2396. | 3.9 | 8 |
| 5 | Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy. European Urology Open Science, 2022, 41, 95-104. | 0.4 | 1 |
| 6 | A case of latent heterozygous Fabry disease in a female living kidney donor candidate. CEN Case Reports, 2021, 10, 30-34. | 0.9 | 7 |
| 7 | Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. Investigative and Clinical Urology, 2021, 62, 166. | 2.0 | 0 |
| 8 | Differential prognostic factors in lowâ€and highâ€burden deÂnovo metastatic hormoneâ€sensitive prostate cancer patients. Cancer Science, 2021, 112, 1524-1533. | 3.9 | 19 |
| 9 | Novel metastatic burdenâ€stratified risk model in de novo metastatic hormoneâ€sensitive prostate cancer. Cancer Science, 2021, 112, 3616-3626. | 3.9 | 8 |
| 10 | EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer. BMC Cancer, 2021, 21, 48. | 2.6 | 19 |
| 11 | Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. Japanese Journal of Clinical Oncology, 2020, 50, 66-72. | 1.3 | 5 |
| 12 | Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. International Journal of Clinical Oncology, 2020, 25, 165-174. | 2.2 | 27 |
| 13 | Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE, 2020, 15, e0236119. | 2.5 | 20 |
| 14 | Potential new therapy of Rapalinkâ€1, a new generation mammalian target of rapamycin inhibitor, against sunitinibâ€resistant renal cell carcinoma. Cancer Science, 2020, 111, 1607-1618. | 3.9 | 38 |
| 15 | Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. Molecular Oncology, 2020, 14, 2190-2202. | 4.6 | 17 |
| 16 | Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. PLoS ONE, 2020, 15, e0232545. | 2.5 | 19 |
| 17 | Successful Kidney Transplantation Alone With Severe Left Ventricular Systolic Dysfunction of Ejection Fraction 14%: A Case Report. Transplantation Proceedings, 2020, 52, 1919-1923. | 0.6 | 1 |
| 18 | A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. International Journal of Clinical Oncology, 2020, 25, 1364-1376. | 2.2 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report. Urology Case Reports, 2019, 26, 100973. | 0.3 | 0 |
| 20 | Tumorâ€'suppressive microRNAâ€'223 targets WDR62 directly in bladder cancer. International Journal of Oncology, 2019, 54, 2222-2236. | 3.3 | 16 |
| 21 | Anatomical Variations of the Left Renal Vein During Laparoscopic Donor Nephrectomy. Transplantation Proceedings, 2019, 51, 1311-1313. | 0.6 | 6 |
| 22 | Potential tumorâ€'suppressive role of microRNAâ€'99aâ€'3p in sunitinibâ€'resistant renal cell carcinoma cells through the regulation of RRM2. International Journal of Oncology, 2019, 54, 1759-1770. | 3.3 | 24 |
| 23 | Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. Journal of Artificial Organs, 2018, 21, 378-382. | 0.9 | 8 |
| 24 | HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. International Journal of Oncology, 2018, 53, 725-736. | 3.3 | 22 |
| 25 | Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report. BMC Nephrology, 2018, 19, 254. | 1.8 | 3 |
| 26 | microRNA Analysis in Prostate Cancer. , 2018, , 267-291. | | 0 |
| 27 | Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. Urology, 2018, 122, 165-168. | 1.0 | 3 |
| 28 | Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. Oncotarget, 2018, 9, 23003-23017. | 1.8 | 28 |
| 29 | Is It Safe to Use the Same Scissors After Accidental Tumor Incision During Partial Nephrectomy? Results of In Vitro and In Vivo Experiments. Journal of Endourology, 2017, 31, 391-395. | 2.1 | 4 |
| 30 | Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. British Journal of Cancer, 2017, 116, 1077-1087. | 6.4 | 48 |
| 31 | PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2Î±-Targeting Therapy for Renal Cell Carcinoma. Cancer Research, 2017, 77, 6321-6329. | 0.9 | 60 |
| 32 | Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. Oncology Reports, 2017, 39, 173-181. | 2.6 | 18 |
| 33 | Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC Cancer, 2017, 17, 677. | 2.6 | 15 |
| 34 | microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget, 2017, 8, 20881-20894. | 1.8 | 57 |
| 35 | Regulation ofUHRF1by dual-strand tumor-suppressormicroRNA-145(miR-145-5pandmiR-145-3p): inhibition of bladder cancer cell aggressiveness. Oncotarget, 2016, 7, 28460-28487. | 1.8 | 93 |
| 36 | The role of microRNAs in bladder cancer. Investigative and Clinical Urology, 2016, 57, S60. | 2.0 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PLoS ONE, 2016, 11, e0148177. | 2.5 | 39 |
| 38 | Tumorâ€suppressive micro<scp>RNA</scp>â€223 inhibits cancer cell migration and invasion by targeting <scp>ITGA</scp>3/<scp>ITGB</scp>1 signaling in prostate cancer. Cancer Science, 2016, 107, 84-94. | 3.9 | 122 |
| 39 | Dual tumorâ€suppressors miRâ€139â€5p and miRâ€139â€3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Science, 2016, 107, 1233-1242. | 3.9 | 115 |
| 40 | Acute Kidney Injury and Rhabdomyolysis After Protobothrops flavoviridis Bite: A Retrospective Survey of 86 Patients in a Tertiary Care Center. American Journal of Tropical Medicine and Hygiene, 2016, 94, 474-479. | 1.4 | 14 |
| 41 | Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. International Journal of Oncology, 2016, 48, 450-460. | 3.3 | 55 |
| 42 | Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. Journal of Human Genetics, 2016, 61, 109-118. | 2.3 | 59 |
| 43 | Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. International Journal of Oncology, 2015, 46, 487-496. | 3.3 | 82 |
| 44 | MicroRNAâ€205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. International Journal of Urology, 2015, 22, 867-877. | 1.0 | 29 |
| 45 | Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 1039-1050. | 3.3 | 40 |
| 46 | MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. International Journal of Oncology, 2015, 47, 710-718. | 3.3 | 62 |
| 47 | The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. International Journal of Oncology, 2015, 47, 325-334. | 3.3 | 24 |
| 48 | Functional significance of aberrantly expressed microRNAs in prostate cancer. International Journal of Urology, 2015, 22, 242-252. | 1.0 | 89 |
| 49 | Tumourâ€suppressive microRNAâ€29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Letters, 2015, 589, 2136-2145. | 2.8 | 66 |
| 50 | MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. British Journal of Cancer, 2015, 113, 1055-1065. | 6.4 | 107 |
| 51 | Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. Journal of Human Genetics, 2015, 60, 53-61. | 2.3 | 61 |
| 52 | Expression of the Tumor SuppressivemiRNA-23b/27bCluster is a Good Prognostic Marker in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1822-1830. | 0.4 | 52 |
| 53 | Tumourâ€suppressive microRNAâ€224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Letters, 2014, 588, 1973-1982. | 2.8 | 76 |
| 54 | The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. Journal of Human Genetics, 2014, 59, 78-87. | 2.3 | 112 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Tumour-suppressivemicroRNA-24-1inhibits cancer cell proliferation through targetingFOXM1in bladder cancer. FEBS Letters, 2014, 588, 3170-3179. | 2.8 | 52 |
| 56 | microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. International Journal of Oncology, 2014, 44, 2085-2092. | 3.3 | 46 |
| 57 | Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. International Journal of Oncology, 2014, 45, 401-410. | 3.3 | 93 |
| 58 | The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster. PLoS ONE, 2014, 9, e84311. | 2.5 | 142 |
| 59 | ThemicroRNA-23b/27b/24-1cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014, 5, 7748-7759. | 1.8 | 115 |
| 60 | Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. International Journal of Oncology, 2013, 43, 1855-1863. | 3.3 | 107 |
| 61 | Tumorâ€suppressive micro<scp>RNA</scp>â€1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Science, 2013, 104, 1411-1419. | 3.9 | 87 |
| 62 | MicroRNA-218 Inhibits Cell Migration and Invasion in Renal Cell Carcinoma through Targeting Caveolin-2 Involved in Focal Adhesion Pathway. Journal of Urology, 2013, 190, 1059-1068. | 0.4 | 102 |
| 63 | Tumorâ€suppressive micro<scp>RNA</scp>â€135a inhibits cancer cell proliferation by targeting the câ€<scp>MYC</scp> oncogene in renal cell carcinoma. Cancer Science, 2013, 104, 304-312. | 3.9 | 87 |
| 64 | Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. International Journal of Oncology, 2013, 42, 1523-1532. | 3.3 | 105 |
| 65 | Aberrant expression of microRNAs in bladder cancer. Nature Reviews Urology, 2013, 10, 396-404. | 3.8 | 200 |
| 66 | MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 115-123. | 1.6 | 78 |
| 67 | Epithelialâ€“mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. Journal of Human Genetics, 2013, 58, 508-516. | 2.3 | 78 |
| 68 | Tumorâ€suppressive micro<scp>RNA</scp>â€143/145 cluster targets hexokinaseâ€2 in renal cell carcinoma. Cancer Science, 2013, 104, 1567-1574. | 3.9 | 118 |
| 69 | Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR. PLoS ONE, 2013, 8, e70372. | 2.5 | 259 |
| 70 | Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. International Journal of Oncology, 2012, 40, 185-93. | 3.3 | 40 |
| 71 | Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. International Journal of Oncology, 2012, 40, 951-959. | 3.3 | 52 |
| 72 | Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. International Journal of Oncology, 2012, 41, 805-817. | 3.3 | 81 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 434-443. | 1.6 | 96 |
| 74 | Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. Journal of Human Genetics, 2012, 57, 691-699. | 2.3 | 97 |
| 75 | Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochemical and Biophysical Research Communications, 2012, 417, 588-593. | 2.1 | 77 |
| 76 | Tumor suppressive microRNA-133a regulates novel targets: Moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2012, 418, 378-383. | 2.1 | 54 |
| 77 | The functional significance of miR-1 and miR-133a in renal cell carcinoma. European Journal of Cancer, 2012, 48, 827-836. | 2.8 | 130 |
| 78 | Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma. International Journal of Oncology, 2012, 40, 1770-8. | 3.3 | 50 |
| 79 | Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. International Journal of Oncology, 2012, 40, 1821-30. | 3.3 | 46 |
| 80 | Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget, 2012, 3, 1386-1400. | 1.8 | 112 |
| 81 | Genomeâ€wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli. International Journal of Urology, 2012, 19, 360-368. | 1.0 | 17 |
| 82 | Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget, 2012, 3, 44-57. | 1.8 | 173 |
| 83 | microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers. Oncotarget, 2012, 3, 9-21. | 1.8 | 218 |
| 84 | Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). Journal of Human Genetics, 2011, 56, 595-601. | 2.3 | 107 |
| 85 | miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. International Journal of Oncology, 2011, 39, 13-21. | 3.3 | 73 |
| 86 | Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. International Journal of Oncology, 2011, 38, 1093-101. | 3.3 | 75 |
| 87 | Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133Î± in head and neck squamous cell carcinoma (HNSCC). International Journal of Molecular Medicine, 2011, 27, 345-52. | 4.0 | 46 |
| 88 | Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. International Journal of Oncology, 2011, 39, 1099-107. | 3.3 | 46 |
| 89 | MiRâ€96 and miRâ€183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Science, 2011, 102, 522-529. | 3.9 | 185 |
| 90 | SWAP70, actinâ€binding protein, function as an oncogene targeting tumorâ€suppressive miRâ€145 in prostate cancer. Prostate, 2011, 71, 1559-1567. | 2.3 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget, 2011, 2, 29-42. | 1.8 | 162 |
| 92 | Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. International Journal of Oncology, 2011, 38, 209-17. | 3.9 | 62 |
| 93 | CpG hypermethylation of cellular retinol-binding protein 1 contributes to cell proliferation and migration in bladder cancer. International Journal of Oncology, 2010, 37, 1379-88. | 3.3 | 16 |
| 94 | miRâ€145, miRâ€133a and miRâ€133b: Tumorâ€suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. International Journal of Cancer, 2010, 127, 2804-2814. | 5.1 | 431 |
| 95 | CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. International Journal of Molecular Medicine, 2010, 26, 241-7. | 4.0 | 20 |
| 96 | Identification of novel microRNA targets based on microRNA signatures in bladder cancer. International Journal of Cancer, 2009, 125, 345-352. | 5.1 | 380 |
| 97 | Epigenetics in bladder cancer. International Journal of Clinical Oncology, 2008, 13, 298-307. | 2.2 | 47 |
| 98 | Increased SKP2 and CKS1 Gene Expression Contributes to the Progression of Human Urothelial Carcinoma. Journal of Urology, 2007, 178, 301-307. | 0.4 | 28 |
| 99 | Nuclear translocation of ADAMâ€10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Science, 2007, 98, 1720-1726. | 3.9 | 55 |
| 100 | p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochemical and Biophysical Research Communications, 2006, 339, 790-796. | 2.1 | 85 |
| 101 | Combination Analysis of Hypermethylated Wnt-Antagonist Family Genes as a Novel Epigenetic Biomarker Panel for Bladder Cancer Detection. Clinical Cancer Research, 2006, 12, 2109-2116. | 7.0 | 166 |
| 102 | Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/Î²-Catenin Signaling Pathway. Clinical Cancer Research, 2006, 12, 383-391. | 7.0 | 181 |
| 103 | Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncology Reports, 2006, 16, 521-31. | 2.6 | 38 |
| 104 | Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene, 2005, 24, 6765-6772. | 5.9 | 81 |
| 105 | CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Molecular Carcinogenesis, 2002, 34, 187-198. | 2.7 | 76 |
| 106 | Reversal of P-Glycoprotein-mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line. Japanese Journal of Cancer Research, 2002, 93, 1037-1046. | 1.7 | 24 |
| 107 | Clinicopathological features of renal cell carcinoma complicated by ACDK in chronic hemodialysis patients.. Nihon Toseki Igakkai Zasshi, 2002, 35, 1495-1501. | 0.1 | 0 |